B. Popova

发表

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.

P. Marsden, J. Radford, P. Schleyer, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

J. Radford, P. Hoskin, M. O'Doherty, 2015, The New England journal of medicine.

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia

A. Hackshaw, P. Veys, B. Dréno, 2017, Leukemia.

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

M. Abbasian, K. Peggs, F. Farzaneh, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients

L. Biasco, R. Hough, P. Amrolia, 2021, Nature Cancer.

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma

S. Darby, J. Radford, D. Cutter, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.

J. Radford, P. Hoskin, S. Barrington, 2020, Blood advances.

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.

J. Radford, P. Hoskin, M. O'Doherty, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

P. Hoskin, T. Illidge, Paul D. Smith, 2014, The Lancet. Oncology.

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

J. Radford, P. Hoskin, M. O'Doherty, 2012 .

Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse

D. Hughes, L. Clifton-Hadley, Paul D. Smith, 2018, British journal of haematology.

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

A. Pettitt, A. Horwich, P. Hoskin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial.

E. Tholouli, S. Mackinnon, K. Peggs, 2022, Cytotherapy.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

G. Lucchini, A. Hackshaw, P. Veys, 2019, Nature Medicine.

A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL

G. Lucchini, A. Hackshaw, P. Veys, 2017 .

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Paul D. Smith, G. Pratt, R. Owen, 2016 .

Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma

R. Cowan, T. Illidge, S. Whittaker, 2013, British Journal of Cancer.

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

D. Hughes, Paul D. Smith, K. Yong, 2016 .

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

G. Lucchini, A. Hackshaw, P. Veys, 2019, Nature Medicine.

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

M. Abbasian, K. Peggs, F. Farzaneh, 2020 .

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Matthew D. Young, S. Behjati, R. Hough, 2023, Nature Medicine.

TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.

R. T. Rego, S. Janes, M. Forster, 2019, Journal of Clinical Oncology.

FoRT: A Phase 3 Multi-Center Prospective Randomized Trial of Low Dose Radiation Therapy for Follicular and Marginal Zone Lymphoma

P. Hoskin, Paul D. Smith, M. Robinson, 2013 .

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

G. Lucchini, A. Hackshaw, P. Veys, 2019, Blood.

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

M. Abbasian, K. Peggs, F. Farzaneh, 2019, Blood.